The effect of arthromac plus in the treatment of knee arthritis

Evaluating and comparing the efficacy of treatment with chondroitin sulfate and hyaluronic acid in patients with knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190226042854N1

Enrollment

Registered

2019-03-17

Start date

2018-04-21

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. Osteoarthritis, unspecified site

Interventions

Intervention 1: Intervention group: Patient right knee

In this group injections of intravenous injection of Arthromc plus, containing 3 ml of hyaluronic acid-chondrocyte sulfate, at a concentration of 20 MG / ML, made in France, NOVATEX BIOENGINEERING. In

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with knee osteoarthritis with clinical and para-clinical diagnostic keratitis suffer from bilateral knee osteoarthritis.

Exclusion criteria

Exclusion criteria: No patient satisfaction Hyaluronic acid hypersensitivity Local skin infection Unilateral DJD

Design outcomes

Primary

Measure	Time frame
Pain score in patients after drug injection based on VAS. Timepoint: 1 month, 3 months, 6 months, 9 months. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Pain; Range of motion ; distance traveled. Timepoint: 1 month, 3 months, 6 months, 9 months. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactasghar abedi

Zanjan University of Medical Sciences

asghar.abedi71@gmail.com+98 41 3741 2698

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026